|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 3.** Clinical course of 14 patients with bone metastases who had ≥2 years of follow-up | | | | | | | | | | | | | |
| Patient | Age | Sex | Histology | Sub-classification | T-Primary Tumor | At the time of initial RAI therapy | | | Re-elevation of Tg†(months) | Cumulative activity of 131I | Subsequent treatment at progression | OS (months) | Outcome |
| The site of metastases | Tg\*  (ng/mL) | TgAb\* (IU/mL) |
| 1 | 40 | Female | Follicular carcinoma | with poorly differentiated component | T3b | Bone | 10460 | 20.3 | 15±3 | 9,250 | Surgery, TT, RT | 42 | Death |
| 2 | 49 | Male | Papillary carcinoma |  | T3a | Lung, bone, LN | 190.9 | <10.0 | N.A. | 2,035 | TT | 128 | Survival |
| 3 | 54 | Male | Follicular carcinoma | with foci of poorly differentiated carcinoma component, minimally invasive | T3 | Bone | 43877.3 | <5.0 | 18±3 | 9,250 | RT, 211At | 60 | Survival |
| 4 | 57 | Female | Papillary carcinoma | follicular variant | TX | Lung, bone | 883.2 | 0.3 | 12±3 | 20,350 | RAI only | 68 | Survival |
| 5 | 64 | Male | Papillary carcinoma |  | T4b | Lung, bone, LN | 233.9 | <10.0 | 30±3 | 2,035 | RT | 129 | Death |
| 6 | 66 | Female | Follicular carcinoma |  | T4a | Lung, bone | 9235.8 | <10.0 | N.A. | 12,950 | RAI only | 50 | Death |
| 7 | 68 | Female | Follicular carcinoma | widely invasive | T1a | Lung, bone, LN | 3462.7 | <5.0 | 46±3 | 24,050 | RT | 79 | Survival |
| 8 | 68 | Female | Follicular carcinoma |  | TX | Bone | 2086.7 | <10.0 | 48±3 | 20,350 | RAI only | 61 | Survival |
| 9 | 70 | Male | Follicular carcinoma | with foci of squamous metaplasia, minimally invasive | T2 | Bone | 4843 | 34.2 | 33±3 | 11,100 | RT | 40 | Survival |
| 10 | 73 | Male | Poorly differentiated carcinoma |  | T4b | Lung, bone, LN | 14937.3 | 29.1 | 35±3 | 16,650 | TT | 51 | Survival |
| 11 | 75 | Male | Follicular carcinoma | oxyphilic cell variant | T4b | Lung, bone, LN, Other sites | 1366.2 | <10.0 | N.A. | 1,850 | TT | 66 | Survival |
| 12 | 76 | Female | Follicular carcinoma |  | T1b | Bone | >5000 | 16.5 | 17±3 | 12,950 | TT | 90 | Death |
| 13 | 80 | Female | Follicular carcinoma | widely invasive | T3 | Lung, bone | 13895.8 | <5.0 | 18±3 | 5,550 | RT | 28 | Death |
| 14 | 82 | Male | Follicular carcinoma |  | T3b | Lung, bone | 13555.3 | <5.0 | 18±3 | 5,550 | RAI only | 64 | Survival |
| Tg, thyroglobulin; TgAb, anti-thyroglobulin antibodies; OS, overall survival; LN, distant lymph nodes; RT, radiation therapy; N.A., Not Available; 211At, Astatine-211; RAI, radioactive iodine; TT, Molecular targeted therapy. \*; The serum Tg and TgAb were measured at the time of initial RAI therapy, Levothyroxine withdrawal. During the observational period, the nadir and subsequent re-elevation of serum Tg† following initial RAI therapy were measured under Levothyroxine therapy. | | | | | | | | | | | | | |